THE USE OF LIPOPHILIC BETA-LACTAM ANTIBIOTICS AND CARBOXYLATE ESTERS FOR THE TREATMENT OF BACTERIAL INFECTIONS WITHIN CITRUS AND OTHER PLANT SPECIES
20200230114 ยท 2020-07-23
Inventors
Cpc classification
A61K47/46
HUMAN NECESSITIES
C07D499/46
CHEMISTRY; METALLURGY
A61K31/43
HUMAN NECESSITIES
International classification
A61K31/43
HUMAN NECESSITIES
Abstract
Disclosed is method for converting a beta-lactam antibiotic into a masked beta-lactam antibiotic to permit it to cross the waxy cuticle of a plant and then subsequently unmasking the beta-lactam and converting it into an active beta-lactam antibiotic in the plant phloem. The method permits the use of beta-lactam antibiotics to be used to treat a variety of plant bacterial infections that was not previously possible because the native beta-lactam antibiotics cannot cross the waxy cuticle of plants. In one embodiment the disclosure finds special use in the treatment of bacterial infection of citrus plants with Huanglongbing disease.
Claims
1. A method for treating a bacterial infection in a plant comprising the steps of: a) providing a beta-lactam antibiotic; b) converting a carboxylate functionality on the beta-lactam antibiotic to an ester function; and c) applying the ester functional beta-lactam from step b) to an outside surface of a plant having a bacterial infection in an amount sufficient to treat the bacterial infection.
2. The method according to claim 1, wherein the beta-lactam antibiotic is one or more selected from the group consisting of penams, carbapenams, oxapenams, monobactams, cephems, carbacephems, oxacephems and mixtures thereof.
3. The method according to claim 1, wherein the beta-lactam antibiotic is one or more selected from the group consisting of penicillin G, penicillin V, and mixtures thereof.
4. The method according to claim 1, wherein step b) comprises combining a beta-lactam antibiotic with an alkyl halide, an aryl halide, an oxymethyl alkyl halide, an oxymethyl aryl halide or a mixture thereof in an organic solvent to form a reaction mixture and reacting the mixture.
5. The method according to claim 4, wherein step b) comprises reacting a beta-lactam antibiotic with a halide selected from the group consisting of a decanoyloxymethyl halide, a pivaloyoxymethyl halide, and a mixture thereof.
6. The method according to claim 4, wherein the solvent comprises N, N dimethylforamide.
7. The method according to claim 4, wherein step b) comprises reacting the reaction mixture at a temperature of at least 25 C. for at least 1 hour.
8. The method according to claim 4, wherein after step b) the reaction is quenched by addition of water and an ester product compound is extracted from the reaction mixture into an organic solvent.
9. The method according to claim 8, wherein the extracted product compound is further passed through a flash column chromatography process purification process.
10. The method according to claim 1 comprising the further step of mixing the ester functional beta-lactam with a carrier vehicle prior to application in step c).
11. The method of claim 10 wherein the carrier vehicle comprises a horticultural oil.
12. The method of claim 11, wherein the horticultural oil is neem oil.
13. The method of claim 12, wherein the carrier vehicle further comprises water.
Description
BRIEF DESCRIPTION OF THE DRAWINGS
[0012] The drawings described herein are for illustrative purposes only of selected embodiments and not all implementations, and are not intended to limit the present disclosure to only that actually shown. With this in mind, various features and advantages of example embodiments of the present disclosure will become apparent from the written description when considered in combination with the appended Figures, wherein:
[0013]
[0014]
[0015]
[0016]
[0017]
[0018]
[0019]
[0020]
[0021]
[0022]
[0023]
[0024]
[0025]
[0026]
[0027]
[0028]
DETAILED DESCRIPTION OF A PREFERRED EMBODIMENT
[0029] The present disclosure is directed toward modification of beta-lactam antibiotics to enable them to cross the waxy cuticle layer and the epidermis of plants to gain access to the phloem. During this movement they are converted back to the active beta-lactam antibiotics and perform their antibiotic function. Water and minerals are absorbed by the roots of trees then transported throughout the tree by the xylem while the phloem transports organic materials synthesized in the leaves of the tree to other parts of the tree. As discussed above the bacterium believed to cause HLB is found in the phloem of infected trees. The bacterial infection interferes with transport of materials in the phloem and leads to death of the tree.
[0030] As discussed above, several of the beta-lactam antibiotics appear to be effective against HLB; however their polar nature, which is a function of the carboxylate group, prevents them from crossing the waxy cuticle layer and the epidermis to gain access to the bacteria in the phloem. The present disclosure is direct to a method for temporarily masking the carboxylate function using an ester modification and enabling the beta-lactam antibiotic to cross the waxy cuticle layer and epidermis of plants.
[0031] In masking the carboxylate group, a number of relatively polar and water soluble penicillin derivatives such as penicillin G, penicillin V, methicillin, cloxacillin, dicloxacillin, flucloxacillin, nafcillin, oxacillin, mecillinam, and others can be converted to considerably more apolar and lipophilic forms. In Table 1 below the calculated log K.sub.ow values are shown for a series of beta-lactam antibiotics that have been converted to ester functions (B and C) versus the native carboxylate function (A). The log K.sub.ow values are the octanol/water partition coefficients for the compounds and represent the concentration in octanol/concentration in water for a compound in an octanol/water two partition solvent as known to one of skill in the art. The values show that converting to one of the two esters dramatically increases the log K.sub.ow values. The R group in the structures below varies by the actual beta-lactam as known to those of skill in the art. For example, for penicillin G the R group is a phenyl group.
TABLE-US-00001 TABLE 1
1. The calculated K.sub.ow A values were calculated only based on the protonated beta-lactam, the carboxylate values would be even less. 2. The calculated values for the pivaloylmethoxy esters B. 3. The calculated values for the decanoylmethyloxy esters C.
[0032] Once these ester compounds are near the phloem, it is believed that the ester functionality is hydrolyzed, via esterase activity or acid catalyzed hydrolysis, back into the active antibiotic carboxylate functionality. The hydrolysis of the ester moiety allows the antibiotic to become both active and to regain its hydrophilic nature allowing the native antibiotic to be transported throughout the phloem network of the plant. The present inventor has developed a means by which he can deliver penicillin derivatives into the phloem of healthy citrus clippings through an external foliar application. These derivatives rely on a temporary lipophilic group which masks the highly polar carboxylate group in the penicillin core as shown in
[0033] The present disclosure presents a method for masking beta-lactam antibiotics that comprises converting the carboxylate function into an ester function. This is accomplished by using the known nucleophilic substitution reaction mechanism, S.sub.N2. A schematic of the reaction mechanism is shown in
EXPERIMENTAL PROCEDURES
[0034] .sup.1H (400 MHz) and .sup.13C (101 MHz) NMR spectra were acquired on a Varian VNMRS-400 instrument using approximately 0.3 M solutions. Chemical shifts are reported in ppm () and are referenced to CDCl.sub.3, 7.27 ppm for .sup.1H and 77.0 ppm for .sup.13C. Coupling constants Ali are in hertz and are reported as follows: chemical shift, multiplicity (br=broad, s=singlet, d=doublet, t=triplet, q=quartet, m=multiplet, hept=heptet, dt=doublet of triplets, dt=doublet of quartets, dd=doublet of doublets), coupling constant, and integration. Melting points were acquired using a Bibby scientific SMP10 melting point apparatus and are uncorrected. Infrared spectra (IR) were recorded with a Shimadzu GladiATR 10 Single Reflection ATR accessory. HPLC analysis was performed using a Beckman Coulter System Gold unit equipped with UV-Vis detection. High-resolution electrospray ionization (HR-ESI) mass spectra were obtained at the Mass Spectrometry Laboratory at the University of California, Irvine. Thin layer chromatography (TLC) used EMD aluminum-backed silica plates (0.20 mm, 60 F-254), and flash chromatography used ICN silica gel (200-400 mesh). Plates were visualized by UV or staining with ceric sulfate/molybdic acid. All commercial reagents and solvents were used as received unless otherwise noted. Yields are reported based on isolated material.
[0035] The general reaction process for forming the ester masked product compounds 1 to 10 shown in
##STR00002##
[0036] Methyl(2S, 5R,6R)-3,3 -dimethyl-7-oxo-6-(2-phenylacetamido)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate (1). A total of 320 mg (92%) methyl ester 1 was obtained as a colorless oil. .sup.1H NMR (400 MHz, CDCl.sub.3) 7.44-7.05 (m, 5H), 6.32 (d, J=8.9 Hz, 1H), 5.59 (dd, J=8.9, 4.2 Hz, 1H), 5.45 (d, J=4.2 Hz, 1H), 4.33 (s, 1H), 3.70 (s, 3H), 3.58 (s, 2H), 1.40 (s, 3H), 1.38 (s, 3H); .sup.13C NMR (101 MHz, CDCl.sub.3) 173.4, 170.5, 168.0, 133.9, 129.7, 128. 8, 127.8, 127.3, 70.4, 68.0, 64.4, 58.9, 52.5, 43.2, 31.9, 26.9; IR (film) v.sub.max 3364, 2963, 2924, 1782, 1744, 1690, 1499, 1451, 1180, 748, 694 cm.sup.1; HRMS (ESI) m/z 349.1209 (M+H.sup.+, C.sub.17H.sub.21N.sub.2O.sub.4S requires 349.1222).
##STR00003##
[0037] Methyl(2S,5R,6R)-3,3-dimethyl-7-oxo-6-(2-phenoxyacetamido)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate (2). A total of 346 mg (95%) methyl ester 2 was obtained as a colorless oil. .sup.1H NMR (400 MHz, CDCl.sub.3) 7.33 (d, J=9.2 Hz, 1H), 7.28-7.23 (m, 1H), 6.97 (t, J=7.4 Hz, 1H), 6.87 (d, J=7.8 Hz, 1H), 5.68 (d, J=4.3, 1H), 5.53 (d, J=4.3, 1H), 4.49 (s, 2H), 4.41 (s, 1H), 3.71 (s, 3H), 1.54 (s, 3H), 1.43 (s, 3H); .sup.13C NMR (101 MHz, CDCl.sub.3) 173.0, 168.0, 156.9, 130.0, 129. 6, 129.5, 122.1, 114.8, 114.6, 70.5, 67.7, 67.1, 64.7, 58.1, 52.5, 31.9, 26.9; IR (film) v.sub.max 3333, 2924, 2854, 1779, 1736, 1686, 1659, 1497, 1211, 910, 725 cm.sup.1; HRMS (ESI) m/z 365.1176 (M+H.sup.+, C.sub.17H.sub.21N.sub.2O.sub.5S requires 365.1171).
##STR00004##
[0038] Benzyl(2S,5R,6R)-3,3-dimethyl-7-oxo-6-(2-phenylacetamido)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate (3). A total of 204 mg (48%) benzyl ester 3 was obtained as a yellow viscous oil. .sup.1H NMR (400 MHz, CDCl.sub.3) 7.50-7.05 (m, 10H), 6.34 (d, J=8.4 Hz, 1H), 5.56 (d, J=4.1 Hz, 1H), 5.39 (dd, J=8.4, 4.1 Hz, 1H), 5.07 (s, 2H), 4.32 (s, 1H), 3.51 (s, 2H), 1.32 (s, 3H), 1.27 (s, 3H); .sup.13C NMR (101 MHz, CDCl.sub.3) 173.4, 170.5, 168.0, 134.8, 133.9, 129.7, 128.9, 128. 8, 128.4, 127.8, 127.3, 122.1, 115.46, 114.0, 70.4, 68.0, 64.8, 64.4, 58.9, 43.2, 31.9, 26.9; IR (film) v.sub.max 3302, 2932, 1780, 1736, 1651, 1497, 1296, 1188, 910, 725 cm.sup.1; HRMS (ESI) m/z 425.1534 (M+H.sup.+, C.sub.23H.sub.25N.sub.2O.sub.4S requires 425.1535).
##STR00005##
[0039] Benzyl(2S,5R,6R)-3,3-dimethyl-7-oxo-6-(2-phenoxyacetamido)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate (4). A total of 247 mg (56%) benzyl ester 4 was obtained as a yellow viscous oil. .sup.1H NMR (400 MHz, CDCl.sub.3) 7.38 (d, J=9.1 Hz, 1H), 7.32 (s, 5H), 7.25 (t, J=8.0 Hz, 2H), 6.97 (t, J=7.4 Hz, 1H), 6.87 (d, J=8.0 Hz, 2H), 5.66 (dd, J=9.1, 4.2 Hz, 1H), 5.52 (d, J=4.2 Hz, 1H), 5.13 (s, 2H), 4.47 (s, 2H), 1.51 (s, 3H), 1.37 (s, 3H); .sup.13C NMR (101 MHz, CDCl.sub.3) 172.9, 167.9, 156.9, 134.7, 130.0, 129.5, 128.9, 128.4, 128.1, 122.4, 122.1, 115.4, 114.8, 114.6, 114.0, 70.3, 67.9, 67.5, 64. 8, 58.3, 58.1, 32.2, 26.8; IR (film) v.sub.max 3294, 3032, 2963, 2870, 1789, 1744, 1651, 1512, 1273, 1211, 1188, 717 cm.sup.1; HRMS (ESI) m/z 441.1484 (M+H.sup.+, C.sub.23H.sub.25N.sub.2O.sub.5S requires 441.1484).
##STR00006##
[0040] (Decanoyloxy)methyl (2S,5R,6R)-3,3-dimethyl-7-oxo-6-(2-phenylacetamido)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate (5). A total of 446 mg (86%) ester 5 was obtained as a colorless viscous oil. .sup.1H NMR (400 MHz, CDCl.sub.3) 7.40-7.07 (m, 5H), 6.43 (d, J=8.8 Hz, 1H), 5.74 (d, J=5.6 Hz, 1H), 5.68 (d, J=5.6 Hz, 1H), 5.56 (dd, J=8.8, 4.2 Hz, 1H), 5.42 (d, J=4.2 Hz, 1H), 4.32 (s, 1H), 3.55 (s, 2H), 2.27 (t, J=7.5 Hz, 2H), 1.54 (p, J=7.1 Hz, 2H), 1.38 (s, 6H), 1.40-1.10 (m, 14H), 0.81 (t, J=6.6 Hz, 3H); .sup.13C NMR (101 MHz, CDCl.sub.3) 173.4, 172.0, 170.6, 166.3, 134.0, 129.7, 129.2, 128.7, 127. 7, 127.2, 79. 5, 69.74, 68.0, 64.4, 59.0, 43.1, 33.7, 31.8, 31.5, 29.3, 29.1, 28.9, 26. 7, 24.4, 22.6, 14.1, 14.0; IR (film) v.sub.max 3309, 2924, 2855, 1759, 1658, 1519, 1103, 725 cm.sup.1; HRMS (ESI) m/z 541.2337 (M+Na.sup.+, C.sub.27H.sub.38N.sub.2O.sub.6SNa requires 541.2348).
##STR00007##
[0041] (Decanoyloxy)methyl(2S,5R,6R)-3,3-dimethyl-7-oxo-6-(2-phenoxyacetamido)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate (6). A total of 352 mg (81%) ester 5 was obtained as a colorless viscous oil. .sup.1H NMR (400 MHz, CDCl.sub.3) 7.33 (d, J=9.2 Hz, 1H), 7.26 (t, J=9.2 Hz, 2H), 6.98 (t, J=7.4 Hz, 1H), 6.87 (d, J=7.9 Hz, 2H), 5.79 (d, J=5.6 Hz, 1H), 5.72 (d, J=5.6 Hz, 1H), 5.69 (dd, J=9.2, 4.3 Hz, 1H), 5.53 (d, J=4.3 Hz, 1H), 4.51 (s, 2H), 4.43 (s, 1H), 2.31 (t, J=7.5 Hz, 2H), 1.62-1.55 (m, 2H), 1.54 (s, 3H), 1.45 (s, 3H), 1.30-1.15 (m, 12H), 0.83 (t, J=7.6 Hz, 1H); .sup.13C NMR (101 MHz, CDCl.sub.3) 173.0, 172.1, 168.0, 166.4, 156.9, 130.0, 129.5, 122.2, 114.8, 114.6, 79.5, 70.0, 67.8, 67.0, 64.7, 58.0, 33.7, 31.8, 29.3, 29.2, 28.9, 26.8, 26.5, 24.5, 22.6, 14.1, 14.0; IR (film) v.sub.max 3341, 2924, 2854, 1759, 1681, 1500, 980, 723 cm.sup.1; HRMS (ESI) m/z 535.2469 (M+H.sup.+, C.sub.27H.sub.39N.sub.2O.sub.7S requires 535.2478).
##STR00008##
[0042] (Pivaloyloxy)methyl (2S,5R,6R)-3,3-dimethyl-7-oxo-6-(2-phenylacetamido)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate (7). A total of 367 mg (82%) ester 7 was obtained as a pale yellow viscous oil viscous oil. .sup.1H NMR (400 MHz, CDCl.sub.3) 7.35-7.10 (m, 5H), 6.82 (d, J=8.2 Hz, 1H), 5.88-5.54 (m, 3H), 5.45 (t, J=4.0 Hz, 1H), 4.35 (s, 1H), 3.54 (s, 2H), 1.41 (s, 6H), 1.15 (s, 9H); .sup.13C NMR (101 MHz, CDCl.sub.3) 176.8, 173.4, 170.4, 166.3, 133.9, 129.7, 129.3, 128.8, 127.8, 127.3, 79.8, 69.8, 68.0, 64.4, 58.9, 50.5, 43.2, 38.7, 31.8, 26.7; IR (film) v.sub.max 3333, 2970, 2877, 1751, 1674, 1490, 1103, 980 cm.sup.1; HRMS (ESI) m/z 471.1571 (M+Na.sup.+, C.sub.22H.sub.28N.sub.2O.sub.6SNa requires 471.1566).
##STR00009##
[0043] (Pivaloyloxy)methyl (2S,5R,6R)-3,3-dimethyl-7-oxo-6-(2-phenoxyacetamido)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate (8). A total of 381 mg (82%) ester 8 was obtained as a pale yellow viscous oil. .sup.1H NMR (400 MHz, CDCl.sub.3) 7.34 (d, J=9.1 Hz, 1H), 7.30-7.21 (m, 2H), 7.01-6.93 (m, 1H), 6.88 (dt, J=13.1, 9.3 Hz, 2H), 5.82 (d, J=5.5 Hz, 1H), 5.73 (d, J=5.5 Hz, 1H), 5.69 (dd, J=9.2, 4.3 Hz, 1H), 5.53 (d, J=4.3 Hz, 1H), 4.52 (s, 2H), 4.44 (s, 1H), 1.54 (s, 3H), 1.47 (s, 3H), 1.17 (s, 9H); .sup.13C NMR (101 MHz, CDCl.sub.3) 176.8, 172.9, 168.1, 166.3, 156.8, 130.0, 129.5, 122.2, 114.8, 114.6, 79.8, 70.0, 67.7, 67.0, 64.7, 58.0, 38.7, 31.8, 26.7; IR (film) v.sub.max 3302, 2970, 2932, 2877, 1751, 1658, 1520, 1103, 980 cm.sup.1; HRMS (ESI) m/z 465.1696 (M+H.sup.+, C.sub.22H.sub.29N.sub.2O.sub.7S requires 465.1695).
##STR00010##
[0044] (Pivaloyloxy)methyl (2S,5R,6R)-3,3-dimethyl-7-oxo-6-(2-phenylacetamido)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate (9). A total of 304 mg (65%) ester 9 was obtained as a brown viscous oil which decomposes upon standing. .sup.1H NMR (400 MHz, CDCl.sub.3) 8.10 (d, J=6.1 Hz, 2H), 7.51 (t, J=8.2 Hz, 1H), 7.50-7.05 (m, 7H), 6.81 (d, J=8.2 Hz, 1H), 5.88-5.54 (m, 3H), 5.45 (t, J=4.0 Hz, 1H), 4.35 (s, 1H), 3.52 (s, 2H), 1.39 (s, 6H); .sup.13C NMR (101 MHz, CDCl.sub.3) 176.9, 172.9, 170.3, 166.0, 133.7, 133.3, 129.8, 129.77, 129.71, 129.3, 128.8, 128.4, 127.8, 127.3, 79.9, 69.8, 68.00, 64.4, 58.9, 50.5, 31.6, 26.8; IR (film) v.sub.max 3240, 2924, 2854, 1718, 1674, 1490, 1103, 1025, 980, 915 cm.sup.1; HRMS (ESI) m/z 491.1244 (M+Na.sup.+, C.sub.24H.sub.24N.sub.2O.sub.6SNa requires 491.1253).
##STR00011##
[0045] (Benzoyloxy)methyl (2S,5R,6R)-3,3-dimethyl-7-oxo-6-(2-phenoxyacetamido)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate (10). A total of 368 mg (76%) ester 10 was obtained as a brown viscous oil which decomposes upon standing. .sup.1H NMR (400 MHz, CDCl.sub.3) 8.09 (d, J=6.4 Hz, 2H), 7.57 (t, J=8.2 Hz, 1H), 7.44 (dd, J=6.4, 8.2 Hz, 2H), 7.36-7.21 (m, 3H), 7.05-6.95 (m, 1H), 6.87 (dt, J=13.0, 9.2 Hz, 2H), 5.83 (d, J=5.5 Hz, 1H), 5.73 (d, J=5.5 Hz, 1H), 5.65 (dd, J=9.2, 4.2 Hz, 1H), 5.51 (d, J=4.2 Hz, 1H), 4.52 (s, 2H), 4.43 (s, 1H), 1.55 (s, 3H), 1.47 (s, 3H); .sup.13C NMR (101 MHz, CDCl.sub.3) 176.7, 173.0, 168.1, 166.0, 156.8, 133.2, 130. 1, 129.79, 129.72, 129.5, 128.3, 122.3, 114.7, 114.5, 80.1, 70.0, 67.8, 67.1, 64.6, 57.9, 31.5, 26.8; IR (film) v.sub.max 3320, 2931, 2856, 1717, 1674, 1490, 1095, 1024, 978, 914 cm.sup.1; HRMS (ESI) m/z 507.1201 (M+Na.sup.+, C.sub.24H.sub.24N.sub.2O.sub.7SNa requires 507.1202).
[0046] Each of the synthesized penicillin derivatives, product compounds 1-10, was applied in a 1:1 mixture with horticultural oil, a dosage of 25 moles of each product compound was applied to the leaves and stems of approximately 0.5 g of Murcott mandarin clippings. The horticultural oil used was neem oil. Neem oil is a vegetable oil pressed from the fruits and seeds of the neem tree, Azadirachta indica, an evergreen tree endemic to the Indian subcontinent. The compounds 1-10 can be dissolved in the neem oil, compounds 1 and 2 formed more of an emulsion than a solution. Once mixed with the neem oil the solutions can be mixed with water and spray applied. The clippings, which consisted of two leaves and an internode, were coated evenly with the product compound while leaving a void region on the bottom to midsection of the internode region to avoid a false positive in the analysis. Once coated, the bottom portion of the internode, which was not coated with any penicillin ester, was submerged in a 1 mL reservoir of tap water and the clipping was allowed to incubate for a 24 hour period. After 24 hours the reservoir water was diluted with 1 mL of methanol, filtered through a nylon 0.2 m microfilter, and analyzed by native mode ESI mass spectrum analysis at an injection rate of 10 mL/min. Untreated clippings and clippings treated only with horticultural oil were used as controls. Through this method of detection, peaks in the mass spectrum were identified that correspond to masses of penicillin G or penicillin V as well as to documented penicillin metabolites for both antibiotics.
EXPERIMENTAL RESULTS
[0047] The general reaction scheme detailed above was used to create the 10 ester derivatives of penicillin G or penicillin V shown in
[0048] The synthesis components and yields for the ten product compounds are shown in Table 2 below. Most of the yields for the S.sub.N2 reaction were moderate to good, ranging from 65-86%, with the exception of (C.sub.6H.sub.5)CH.sub.2Br which gave relatively low yields of 48% and 56% of the benzyl esters of penicillin G and penicillin V respectively. Methyl esters, product compounds 1 and 2, both were formed with exceptional yields of 92% for penicillin G and 95% for penicillin V.
TABLE-US-00002 TABLE 2 Alkyl or Product % yield after Penicillin Aryl halide compound purification G CH.sub.3I 1 92 G (C.sub.6H.sub.5)CH.sub.2Br 3 48 G ClCH.sub.2O.sub.2C(CH.sub.2).sub.8CH.sub.3 5 86 G ClCH.sub.2CO.sub.2C(CH.sub.3).sub.3 7 82 G ClCH.sub.2OCO(C.sub.6H.sub.5) 9 65 V CH.sub.3I 2 95 V (C.sub.6H.sub.5)CH.sub.2Br 4 56 V ClCH.sub.2O.sub.2C(CH.sub.2).sub.8CH.sub.3 6 81 V ClCH.sub.2CO.sub.2C(CH.sub.3).sub.3 8 82 V ClCH.sub.2OCO(C.sub.6H.sub.5) 10 76
[0049] The negative ESI mass spectrum of the reservoir water for clippings treated with the product compounds 1-10 and the controls are shown in
[0050] The decanoyloxymethyl, product compounds 5 and 6, and the pivaloyloxymethyl esters, product compounds 7 and 8, displayed the most promising results in which the base peaks in the mass spectrum corresponded to the active antibiotics penicillin G at approximately 333 m/z (332.60 to 332.67) or penicillin V at approximately 349 m/z (348.67 to 348.87) and/or known metabolites with an identical molecular weight. See the results shown in
[0051] A small library of ten penicillin G and V esters were evaluated for their ability to penetrate the waxy cuticle layer and to be converted into active antibiotics by citrus tissue. Product compounds 1, 2, 5, 6, 7, and 8 all appear to affectively penetrate through the waxy cuticle layer and through the epidermis to access the phloem within Murcott mandarin clippings. However, only product compounds 5, 6, 7, and 8 appeared to be hydrolyzed into the active antibiotic. The results suggest that product compounds 5, 6, 7, and 8 could be used as a method for delivering beta-lactam antibiotics into the phloem of citrus plants infected with Candidatus liberbacter, and therefore could serve as a means of treating HLB disease. This delivery mechanism is far more effective, practical, economical, and considerate of environmental antibiotic resistance compared to the current methods being applied, especially when considering that in our system active antibiotics are only produced by esterase activity that occurs within the citrus plant. It is believed that the masking process of the present disclosure will enable modification of a variety of beta-lactam antibiotics and open up their use to combat plant bacterial infections that currently cannot be controlled. The ester masked beta-lactam can be applied to the outside surface of a plant with a bacterial infection to control or prevent the infection. The amount of ester masked beta-lactam applied to a plant will be determined in part by the activity of the beta-lactam against the particular infection, the degree of infection and other factors known to one of skill in the art. Exemplary classes of beta-lactam antibiotics that could be used in the present disclosure and method include: penams, carbapenams, oxapenams, monobactams, cephems, carbacephems, oxacephems and mixtures thereof. Suitable penams and carbapenams include, by way of example only and not limitation, benathine penicillin, benzylpenicillin (penicillin G), phenoxymethylpenicillin (penicillin V), procaine penicillin, cloxacillin, dicloxacillin, flucloxacillin, methicillin, nafcillin, oxacillin, temocillin, amoxicillin, ampicillin, mecillinam, carenicillin, ticarcillin, azlocillin, mezlocillin, piperacillin, biapenem, doripenem, ertapenem, faropenem, imipenem, meropenem, panipenem, razupenem, tebipenem, and thienamycin. Suitable cephems and carbacephems include, by way of example only and not limitation, cefazolin, cephalexin, cephalosporin C, cephalothin, cefaclor, cefamandole, cefuroximine, cefotetan, cefoxitin, cefixime, cefotaxime, cefpodoxime, ceftazidime, ceftriaxone, cefepime, cefpirome, and ceftaroline. Suitable monobactams include, by way of example only and not limitation, aztreonam, tigemonam, nocardicin A, and tabtoxinine -lactam.
[0052]
[0053] The foregoing disclosure has been described in accordance with the relevant legal standards, thus the description is exemplary rather than limiting in nature. Variations and modifications to the disclosed embodiment may become apparent to those skilled in the art and do come within the scope of the disclosure. Accordingly, the scope of legal protection afforded this disclosure can only be determined by studying the following claims.
[0054] The foregoing description of the embodiments has been provided for purposes of illustration and description. It is not intended to be exhaustive or to limit the disclosure. Individual elements or features of a particular embodiment are generally not limited to that particular embodiment, but, where applicable, are interchangeable and can be used in a selected embodiment, even if not specifically shown or described. The same may also be varied in many ways. Such variations are not to be regarded as a departure from the disclosure, and all such modifications are intended to be included within the scope of the disclosure.
[0055] Example embodiments are provided so that this disclosure will be thorough, and will fully convey the scope to those who are skilled in the art. Numerous specific details are set forth such as examples of specific components, devices, and methods, to provide a thorough understanding of embodiments of the present disclosure. It will be apparent to those skilled in the art that specific details need not be employed, that example embodiments may be embodied in many different forms and that neither should be construed to limit the scope of the disclosure.
[0056] In some example embodiments, well-known processes, well-known device structures, and well-known technologies are not described in detail.
[0057] The terminology used herein is for the purpose of describing particular example embodiments only and is not intended to be limiting. As used herein, the singular forms a, an, and the may be intended to include the plural forms as well, unless the context clearly indicates otherwise. The terms comprises, comprising, including, and having, are inclusive and therefore specify the presence of stated features, integers, steps, operations, elements, and/or components, but do not preclude the presence or addition of one or more other features, integers, steps, operations, elements, components, and/or groups thereof. The method steps, processes, and operations described herein are not to be construed as necessarily requiring their performance in the particular order discussed or illustrated, unless specifically identified as an order of performance. It is also to be understood that additional or alternative steps may be employed.